16 October 2019 | News
The three drugs will currently be sold in India and patent-free markets worldwide
New Delhi based Morepen Laboratories Ltd. has developed and added three blockbuster drugs to its portfolio of Active Pharmaceutical Ingredients (APis) for sale in domestic and global markets.
The three bulk drugs / APis are Rivaroxa ban (trade nameXarelto), Vildagliptin (trade names- Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid). While two products Rivaroxaban and Yildagliptin will augment Morepen's presence in the Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver segment.
The current global market size for Rivaroxaban, a powerful anticoagulant (blood thinner), is $7.1 9Billion (Rs. 51,000 cores) and that ofVildagliptin, which is a strong oral Anti-diabetic drug used for the treatment of type 2 diabetes, is $1.28 Billion (Rs. 9,000 cores).
The global market size for Rivaroxaban is likely to touch $9.00 Billion(Rs. 64,000 crore) by year 2023 and that of Yildagliptin $1.35 Billion (Rs. 9,600 crore) by 2021 . Morepen Labs will initially target patent free markets for these two drugs globally.
The Drug Master File (DMF) for regulatory markets like US etc will be filed within the next 12 months' time frame.